Crucell N.V. (ADR) (CRXL)

CRXL has some of the best technology for making vaccines. Guess what? This is the era of vaccines! You hear about it everyday in the media. Target $28.00

Crucell is involved in every major vaccine program in the world including TB, malaria, HIV and ebola. In addition with it proprietary technology including PERc.6, AdVac and MabAbstract they are miles ahead of competitors. In addition with over 80 partners having clinical trials underway the royalty income should be substantial within the next 5 years. With the US government support and recent partnership with JNJ Crucell ,may turn the Flu vaccine business totally around with their Universal flu antibody and a possible universal flu vaccine. The company is grossly undervalues and under the radar and presently has over 600 million in cash

Crucell, the seventh-largest vaccine maker in the world, sells the flu vaccine Inflexal. Mild flu seasons over the last two years have made it difficult for Crucell to grow its flu vaccine franchise. But if advance orders from competing firms are any indication, Crucell could increase its seasonal flu vaccine sales by at least 50% this year. That could translate to an extra, unexpected $40 million in revenue. For a firm with about $400 million in sales, that's no chump change.

Crucell has shown strong growth this year compared to the biopharmaceutical industry as a whole and doesn’t seem to be slowing down with strong financials and a good debt to equity ratio.

still a take over candidate-- mass production and quick delivery of vaccines

this is a company that develops products which will become more and more valuable to the wellbeing of all on earth.

Biopharma - vaccines and antibodies.

Vaccines are lower risk, but still have a nice profit margin

CAPS Stock of the Day for me today -- this Friday. It follows one of the worst two-week periods in market history -- itself coming after a really bad bunch of months. The S&P 500 has declined more than 40% over the past 12 months. This is, quite simply, unbelievable.

The market is oversold. Up-and-comers like Crucell are off 20%+ in just a matter of days. Let's just see, Fools, shall we...? Let's just see how many of the positions I open tonight beat the market over the next 2-4 years. Ready, set, go. --David

This has been a frustrating stock for me. I really like this company, I like vaccines, but it seems to trade under 20. I like the price to get in to here, but they really need to make some headway in a marketable vaccine. They were operating cash flow even for a second there - some earnings would be nice. I suspect short interest pinning this dude down. I think it is pretty safe to enter at this level, but not sure of the upside potential unless we get a catalyst for growth.

Crucell cames out with excellent quartery numbers and this vaccine mfgr. should rise quickly as a result. Its recent acquisitions also will help this Amsterdam company .

best technology for producing vaccines, licensing to more and more drug companies, making vaccines for bird flu, rabies, etc. As more nations grow prosperous, spending for vaccines will grow.

Biotech company that develops cell based vaccins as the safe replacement for the egg based process. Many licensees of a growing list. Works with companies like Merck, DSM, Sanofi Pasteur, Novartis. Acquired Berna and SBL Vaccines to market and sell traveller vaccines, quinvaccin for childhood diseases. Fair value was estimated between $ 30 and $50 dollars a year ago. Stockprice has fallen below $20 below the stockjprice were financials stepped in more than a year ago. Resaarch in the field of recombinant proteins like blood factors for the replacement of plasma products can have an enormeous impact on the profitability. I think that we have seen the bottom and will pick it up again.

Fast and cheap biologicals

per.C6 a break through in vaccine tech

a two for the price of one company; a global vaccine company and a development and licensing co. for their technology base (Per C-6; STAR and ADVAC); Vaccine-part will provide (cash)basis for development of further vaccines; this is the basis for stock price next 2 to 3 years. The licensing/technology base is actually were the real money can be in a couple more years. Their technology (Per C6 and STAR) is close to becoming an industry standard, with the possibility of Crucell becoming a sort of biotech Microsoft.

This biotech will continue to grow.

Finally up over 26. Berna acquisition now in back poket...Crxl will begin to move upward with its fantastic Tech. Companies will begin to line up for a piece.

infectious disease vaccines...welcome to the new world